Oncology Peer Review On-The-Go: Academic Promotion and Oncology Drug Development

Podcast

Nora Janjan, MD, MPSA, MBA, spoke with CancerNetwork® about the latest perspective from the journal ONCOLOGY® on how roles and responsibilities of academic clinicians in reporting of conflicts of interest influence oncology research.

Nora Janjan, MD, MPSA, MBA, who sits on the editorial advisory board for the journal ONCOLOGY®, spoke about her perspective titled, ‘Academic Promotion and Oncology Drug Development: Role, Responsibilities, and Integrity.’

In the article, Janjan explores the role conflicts of interests (COIs) play in research integrity and how individual investigators are upholding their end of the deal by practicing safe reporting of relationships with the industry. Her narrative complements a cross-sectional study of junior faculty at major academic cancer centers to evaluate patterns of COIs with years of clinician experience to determine if increasing COIs and industry funding correlate with greater academic success.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Recent Videos
Optimal cancer survivorship care may entail collaboration between a treating oncologist and a cancer survivorship expert.
Survivors of cancer may experience an increased risk of having organ, cardiac, or lung disease following prior anti-cancer therapy.
Performing ablation and injecting tumor sites with immunotherapy may be “synergistic”, according to Jason R. Williams, MD, DABR.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
The Together for Supportive Cancer Care coalition may advance the national conversation in ensuring comprehensive care for all patients with cancer.
Health care organizations have come together to form the Together for Supportive Cancer Care coalition to address gaps in supportive cancer care services.
Further optimizing a PROTAC that targets MDM2 may lead to human clinical trials among patients with cancer harboring p53 mutations.
Related Content